Business Context and Reporting Period
Company: Clover Health Investments, Corp. (CLOV)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Clover Health operates Medicare Advantage (MA) plans (PPO and HMO) in five states and 203 counties. Its strategy relies on "Clover Assistant," a proprietary AI-driven software platform that empowers physicians to manage chronic diseases earlier. The company also launched "Counterpart Health" in 2024 to license this technology to external payors and providers. As of December 31, 2025, the company had 113,803 insurance members.
Key Financial Metrics
| Metric (in thousands, except ratios) | 2025 | 2024 |
|---|---|---|
| Total Revenues | $1,924,308 | $1,371,131 |
| Premiums Earned, Net | $1,891,732 | $1,344,881 |
| Net Medical Claims Incurred | $1,568,406 | $1,006,327 |
| Consolidated Gross Profit (Non-GAAP) | $355,902 | $364,804 |
| Net Loss from Continuing Operations | $(85,549) | $(46,266) |
| Adjusted EBITDA (Non-GAAP) | $21,695 | $70,091 |
| Adjusted Net Income (Non-GAAP) | $19,989 | $68,243 |
| Cash, Cash Equivalents, and Investments | $319,900 | $437,600 |
| Unpaid Claims Liability | $153,250 | $156,396 |
| Insurance Benefits Expense Ratio (BER) | 90.9% | 81.2% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 40.3% to $1.92 billion, driven primarily by a 33% increase in average members and higher risk adjustment revenue.
- Widening Losses: GAAP Net Loss from continuing operations increased 84.9% to $85.5 million. This was driven by a 55.9% increase in net medical claims incurred ($562 million increase), which outpaced revenue growth.
- Deteriorating Margins: The Insurance Benefits Expense Ratio (BER) worsened significantly from 81.2% in 2024 to 90.9% in 2025. The Normalized BER increased from 84.2% to 91.5%.
- Decline in Non-GAAP Profitability: Adjusted EBITDA fell 69% to $21.7 million, and Adjusted Net Income dropped 71% to $20.0 million, reflecting higher medical costs and increased general and administrative expenses.
- Cash Flow: Operating cash flow turned negative, with $66.9 million used in operating activities in 2025, compared to $82.5 million provided in 2024.
Guidance, Outlook, and Risks
- Membership Growth: The company reported a 53% year-over-year growth in MA membership during the 2026 Annual Election Period, entering 2026 with over 153,000 members.
- Star Ratings: CMS decreased the Star Rating for PPO plans to 3.5 Stars for the 2026 rating year (affecting 2027 payments), while the HMO plan rating increased to 4.0 Stars. Lower ratings can limit enrollment opportunities and bonus payments.
- Medical Cost Management: Management highlighted that profitability depends on the ability to predict and manage medical costs. The increase in the BER was attributed to growth in average members, changes in Part D cost sharing due to the Inflation Reduction Act, and less favorable prior period development compared to 2024.
- Regulatory and Legal Risks: The company faces ongoing risks related to CMS risk adjustment audits, potential retroactive adjustments to revenue, and investigations into fraud, waste, and abuse. The company is subject to the False Claims Act and Anti-Kickback Statute.
- Capital Needs: The company may require additional capital to support growth. It exhausted its $20 million share repurchase program in Q1 2025.
Investor Verification Checklist
- Medical Loss Ratio Trend: Verify the sustainability of the 90.9% BER and the drivers behind the 9.7 percentage point increase from 2024. Assess if this trend is temporary or structural.
- Star Rating Impact: Confirm the financial impact of the PPO Star Rating downgrade to 3.5 Stars on future premium revenue and bonus payments.
- IBNR Reserves: Review the actuarial assumptions for Incurred But Not Reported (IBNR) claims, which totaled $115.1 million (75.1% of unpaid claims), as variances here directly impact future earnings.
- Counterpart Health Viability: Assess the progress and revenue contribution of the Counterpart Health SaaS subsidiary, which is currently not significant to overall results but is a key growth strategy.
- Liquidity Position: Monitor the decline in total cash and investments from $437.6 million to $319.9 million and the shift to negative operating cash flow.